Is PT-141 (Bremelanotide) Legal in Arizona?
HealthRX.com
Vyleesi is the only FDA-approved bremelanotide product
See the public record for Bremelanotide
At a glance
- Drug / Bremelanotide, brand Vyleesi; PT-141 is the name used in earlier studies [3]
- FDA status / Approved June 21, 2019, NDA 210557, prescription only [1][2]
- Approved for / Premenopausal women with acquired, generalized HSDD [1]
- Dose and form / 1.75 mg subcutaneous autoinjector, as needed, at least 45 minutes before activity [1]
- Boxed warning / None; no REMS in the label or the 2019 approval letter [1][2]
- Compounded or research-use PT-141 / Not the FDA-approved product; not FDA-reviewed before marketing [4]
What the federal approval covers
Vyleesi is a 1.75 mg subcutaneous injection in a prefilled autoinjector, prescription only, approved under NDA 210557 on June 21, 2019 [1][2]. The label has no boxed warning, and no risk evaluation and mitigation strategy appears in the label or the approval letter [1][2].
Vyleesi is the only FDA-approved bremelanotide product. Anything sold as PT-141 by a compounding pharmacy or research-peptide vendor is not Vyleesi and is not an FDA-approved drug; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [1][4]. Bremelanotide is not on FDA's list of bulk substances that may present significant safety risks when compounded (content dated April 22, 2026), not in any category on FDA's bulk-substance lists, and not among the six peptides in HHS's October 2026 draft enforcement-discretion policy [5][6][7].
Who it is approved for
Vyleesi is for premenopausal women with acquired, generalized HSDD: low sexual desire causing marked distress or interpersonal difficulty that is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label states it is not indicated for postmenopausal women, not indicated in men, and not indicated to enhance sexual performance [1].
PT-141 has been tested in men. A 2004 trial gave single subcutaneous doses of 0.3 to 10 mg to healthy male volunteers and 4 or 6 mg to men with erectile dysfunction who responded poorly to sildenafil, with statistically significant erectile responses above 1.0 mg and at both doses in the erectile dysfunction group [3]. That work sits outside the labeled indication [1].
What the label flags for anyone filling a prescription
The label contraindicates Vyleesi in uncontrolled hypertension or known cardiovascular disease and says it is not recommended in people at high cardiovascular risk [1]. Each dose transiently raises blood pressure, with maximal increases of 6 mmHg systolic and 3 mmHg diastolic peaking 2 to 4 hours after the dose, and heart rate falling up to 5 beats per minute [1].
Nausea was reported by 40% of patients versus 1.3% on placebo; 13% took an anti-nausea medicine and 8% discontinued the trials over it [1]. Focal hyperpigmentation of the face, gums or breasts was reported by 1% of patients taking up to 8 doses a month versus none on placebo [1]. The label says to avoid oral naltrexone products intended to treat alcohol or opioid addiction, because Vyleesi may significantly decrease naltrexone blood levels [1].
The label's recommended dose is 1.75 mg into the abdomen or thigh at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours; it says more than 8 doses per month is not recommended and to stop after 8 weeks if there is no improvement in symptoms [1].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Questions worth asking
Frequently asked questions
Is PT-141 (bremelanotide) legal in Arizona?
Is compounded PT-141 the same thing as Vyleesi?
Who is bremelanotide approved for?
References
Show all 7 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-42.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.